Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people <55 years. Here, we report the saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Pannus, Pieter, Depickère, Stéphanie, Kemlin, Delphine, Houben, Sarah, Neven, Kristof Y., Heyndrickx, Leo, Michiels, Johan, Willems, Elisabeth, De Craeye, Stéphane, Francotte, Antoine, Chaumont, Félicie, Olislagers, Véronique, Waegemans, Alexandra, Verbrugghe, Mathieu, Schmickler, Marie-Noëlle, Van Gucht, Steven, Dierick, Katelijne, Marchant, Arnaud, Desombere, Isabelle, Ariën, Kevin K., Goossens, Maria E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021431/
https://www.ncbi.nlm.nih.gov/pubmed/36962838
http://dx.doi.org/10.1371/journal.pgph.0001308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021431/
https://www.ncbi.nlm.nih.gov/pubmed/36962838
http://dx.doi.org/10.1371/journal.pgph.0001308

Ejemplares similares